RIBOLIFE-B(06938): RBD5044 implies permission for Phase II clinical trials in China.

RIBOLIFE-B (06938) announced that the self-developed RBD5044 injection has obtained the Phase II clinical trial implied approval from the China National Medical Products Administration. RBD5044 is a siRNA drug targeting APOC3. APOC3 is a protein synthesized almost exclusively in the liver, playing a key role in lipid metabolism. RBD5044 can address complications associated with hypertriglyceridemia, becoming a treatment option for managing lipid disorders.